Adding to the mystery, neighbors said police confiscated a white Ford pick-up truck Friday morning belonging to the victim's roommate.

The ASX may be at highs, but some quality names still look undervalued. The post I'm listening to Warren Buffett and buying cheap ASX shares appeared first on The Motley Fool Australia.

A new family festival is coming to Carlisle this autumn. EdenFest26 will take place on Saturday, September 19, at Carlisle Cricket Club, Edenside, running from 12pm to 8pm. Organisers say the new ...

Asian stocks took some positive cues from Wall Street, which firmed mildly in overnight trade on a mixed recovery in tech.

Investing.com-- Australian biopharma firm CSL Ltd (ASX:CSL) said on Wednesday it entered an exclusive licensing agreement with Eli Lilly and Company (NYSE:LLY) granting the latter rights to develop ...

The most recent earnings report from CSL Limited (ASX:CSL) was disappointing for shareholders. Despite the soft profit numbers, our analysis has optimistic about the overall quality of the income ...

Under terms of the allocation deal, Carlisle Development Parters will pay $14 million over the next five years for the right ...

At five minutes past 4 o’clock on Tuesday afternoon, one of the country’s largest listed companies and an absolute ASX stalwart announced to the sharemarket that its chief executive had resigned. The ...

The worst US flu season in decades did not shield one of Australia’s largest companies, biotechnology firm CSL, from another brutal market response as vaccine scepticism from Trump administration ...

CSL announced the exit of Paul McKenzie as chief executive. Senior executive Gordon Naylor appointed interim CEO. Shares of Australian biotech firm CSL plunged to an 8-year low Wednesday after it ...

CSL's underlying earnings fell in the first half, but management stuck to its full-year guidance and boosted the buy-back. The CSL Ltd (ASX: CSL) share price is in focus today after reporting ...

Chairman and former boss Brian McNamee has claimed the departing CEO didn’t have the skills to steer the global biotech’s future. The turmoil at the top adds to a horror six months for CSL. In that ...